Sandoz Group Ltd ( (CH:SDZ) ) just unveiled an update. Sandoz has announced a potential acquisition of Just-Evotec Biologics’ activities in Toulouse, France, aiming to enhance its biosimilar ...

In Q2, the FDA approved two biosimilars in the ustekinumab and bevacizumab markets and four biosimilars were launched within ...

Each year, the FDA approves a wide range of medications that help shape the future of medicine in the U.S. These include ...

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 ...

The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...

Though India has built a robust domestic biosimilar market, its international presence and the ability to lower prices as ...

Biosimilar drugs are drugs that are a lot like biologics, but maybe not identical. Learn why this matters inside.

Tiffany E Jiang , Reshma Ramachandran , and Joshua J Skydel argue that US requirements for interchangeability are not supported by evidence and hamper use of biosimilars Biological medicines ...

As with other therapeutic categories, penetration of biosimilar insulin products in the European market long predates the U.S. Across Europe, biosimilar insulin products began to launch in 2015.

Biosimilar Approvals And The BPCIA: Too Soon To Give Up Jonathan J. Darrow July 19, 2019 10.1377/forefront.20190718.722161 Add to favorites ...

Whether it is the biosimilar status, or the interchangeable designation, or—also likely—simply lower-price contracting, pharmacy benefit managers have started to embrace this product.